Table 2 Shows baseline characteristics of the included studies
Study ID | Group Name | Number assessable | Age (yrs. mean ± SD (range)) | Sex (male no (%)) | Primary cancer site n(%) | Stage of disease | Cisplatin dosage per cycle | |
|---|---|---|---|---|---|---|---|---|
head and neck | other | Advanced/metastatic | ||||||
Riga 2013 | N-acetylcysteine/control group | 20 | 52 ± 16.3 (16–77) | 15 (75%) | 5 (25%) | 15 (75%) | 19 (95%) | 50–100 mg/m2 |
Yoo 2014 | N-acetylcysteine/ control group | 11 | 53.6 ± 10.3 (29–68) | 12 (92.3%) | 13 (100%) | 0 (0%) | 11 (100%) | 100 mg/m2 body surface area |
Sarafraz 2018 | N-acetylcysteine/ dexamethasone group | 57 | 32.4 ± 22.1 (6–60) | 26 (45.6%) | 10 (17.5%) | 47 (82.5%) | ||